quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:00:00·21d
PRRelease
Esperion Therapeutics Inc. logo

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

ESPR· Esperion Therapeutics Inc.
Health Care
Original source

Companies

  • ESPR
    Esperion Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Nov 25UpdatePiper Sandler$9.00
  • Dec 18UpdateGoldman$4.00
  • Dec 17UpdateCantor Fitzgerald$8.00
  • Jun 20UpdateBofA Securities$2.50
  • Jan 3UpdateBofA Securities-
  • Nov 20UpdateJP Morgan-

Related

  • PR1d
    Esperion to Report First Quarter 2026 Financial Results on May 7
  • SEC1d
    SEC Form SCHEDULE 13G filed by Esperion Therapeutics Inc.
  • SEC7d
    SEC Form DEFA14A filed by Esperion Therapeutics Inc.
  • SEC7d
    SEC Form DEF 14A filed by Esperion Therapeutics Inc.
  • SEC21d
    Esperion Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
  • PR21d
    Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
  • PR24d
    Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
  • PR25d
    Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022